Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

Exclusion criteria

• ✕. Sexually active women of childbearing (WOCBP)\* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for 20 months after the final dose of treatment. Highly effective contraceptive measures include:
• ✕. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation
• ✕. Intrauterine device (IUD); intrauterine hormone-releasing system
• ✕. Bilateral tubal ligation;
• ✕. Vasectomized partner (provided that the vasectomized partner is the sole sexual partner of the WOCBP study subject);
• ✕. and/or sexual abstinence.
• ✕. Sexually active males who are unwilling to use a condom with female partners of childbearing potential, during the study, and for at least 8 months after the last dose of treatment.
• ✕. Subjects who plan on donating blood or blood products during the study and for at least 20 months after the last dose of treatment. Male subjects must agree not to donate sperm during the study and for at least 8 months after the last dose of treatment.